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ABSTRACT
Topoisomerase II (Top2) is an essential enzyme that
decatenates DNA via a transient Top2-DNA cova-
lent intermediate. This intermediate can be stabilized
by a class of drugs termed Top2 poisons, resulting
in massive DNA damage. Thus, Top2 activity is a
double-edged sword that needs to be carefully con-
trolled to maintain genome stability. We show that
Uls1, an adenosine triphosphate (ATP)-dependent
chromatin remodelling (Snf2) enzyme, can alter Top2
chromatin binding and prevent Top2 poisoning in
yeast. Deletion mutants of ULS1 are hypersensitive to
the Top2 poison acriflavine (ACF), activating the DNA
damage checkpoint. We map Uls1′s Top2 interaction
domain and show that this, together with its ATPase
activity, is essential for Uls1 function. By performing
ChIP-seq, we show that ACF leads to a general in-
crease in Top2 binding across the genome. We map
Uls1 binding sites and identify tRNA genes as key
regions where Uls1 associates after ACF treatment.
Importantly, the presence of Uls1 at these sites pre-
vents ACF-dependent Top2 accumulation. Our data
reveal the effect of Top2 poisons on the global Top2
binding landscape and highlights the role of Uls1 in
antagonizing Top2 function. Remodelling Top2 bind-
ing is thus an important new means by which Snf2
enzymes promote genome stability.
INTRODUCTION
All eukaryotic genomes are organized into chromatin; a
complex arrangement of DNA and associated binding pro-
teins. Due to the relative inaccessibility of DNA within
chromatin, a universal problem facing eukaryotes is how
to access their genetic information. One of the means by
which this is achieved is bymechanically altering local chro-
matin structure through the action of adenosine triphos-
phate (ATP)-dependent chromatin remodelling (Snf2) en-
zymes (1). These proteins are ubiquitous amongst eukary-
otes (2) and their influence on chromatin structure means
that Snf2 proteins affect all DNA-based transactions such
as DNA transcription, replication and repair (3). Under-
scoring their importance, mutations within human Snf2
proteins cause a range of developmental disorders (4,5)
and SWI/SNF is the most commonly mutated chromatin-
regulatory complex in human cancers (6). The majority of
Snf2 proteins act by remodelling nucleosomes (1). How-
ever, some Snf2 proteins have been shown to act on non-
nucleosomal DNA binding proteins such as TBP (7,8) and
Rad51 (9–11). Indeed, for others, their functions remain
largely unknown. Here, we use budding yeast to study one
such Snf2 factor, ULS1 and find that its deletion results in
hypersensitivity to the Topoisomerase II (Top2) poison acri-
flavine (ACF).
Top2 is an essential mediator of genome stability due to
its ability to disentangle DNA molecules and resolve DNA
torsional stress (12). Loss of Top2 causes irreparable defects
in cell division whereas blocking Top2 catalytic activity in-
duces massive DNA damage and checkpoint arrest (13). As
part of its reaction cycle, Top2 forms a transient protein–
DNA adduct termed the cleavage complex (12). If this in-
termediate is not resolved, it results in the formation of a
DNA single-strand or double-strand break next to a cova-
lent Top2–DNA adduct (14,15); both highly cytotoxic le-
sions. This enzymatic weakness is targeted by Top2-poisons,
which act to stabilize the cleavage complex (15). This is
in contrast to the mechanism of Top2 catalytic inhibitors,
which do not stabilize cleavage complex formation (16). The
ability of Top2 poisons to turn Top2′s enzymatic activity
against itself makes them an important class of anti-cancer
drugs. However, even in non-cancerous cells, excess topoi-
somerase activity is potentially dangerous as it increases the
probability that some topoisomerase molecules will stall as
cleavage complexes. Several endogenous protein inhibitors
of topoisomerase activity exist in bacteria (17–19). There-
fore, it is perhaps a little surprising that equivalent eukary-
otic topoisomerase inhibitors have not previously been de-
scribed.
We find that Uls1 helps to keep Top2 activity in check
by altering its chromatin association. Uls1 binds Top2 via
a Top2-interaction domain (amino acids 350–655) and has
DNA-stimulated ATPase activity. Both Uls1′s Top2 inter-
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action domain andATPase activity are essential for its func-
tion, consistent with the idea that it remodels chromatin-
boundTop2. This is in agreement with a recent report show-
ing that the homolog of Uls1 in the distantly related yeast
Schizosaccharomyces pombe, can displace Top2 from DNA
(20). Moreover, we extend these observations by mapping
how Uls1 influences the genome-wide binding distribution
of Top2 in vivo. Using ChIP-seq, we show that ACF causes
a general increase in Top2 binding across the genome, ex-
cept at Uls1 binding sites. Thus, the presence of Uls1 is
sufficient to displace Top2 from chromatin after exposure
to ACF. Uls1 binding sites are distributed throughout the
genome but, in the presence of ACF, become enriched
at tRNA genes. Interestingly, many tRNA genes show a
ULS1-dependent decrease in Top2 binding after ACF treat-
ment. This reveals unexpected complexity in the function of
Uls1 and suggests that targeting related human Snf2 pro-
teins may reduce the toxicity associated with Top2 poisons
by sensitizing cancers to these drugs (21,22).
MATERIALS AND METHODS
Yeast strains
A full strain list (Supplementary Table S1) and plasmid list
(Supplementary Table S2) can be found in supplementary
information.
Protein expression and purification
Full length Top2 (HFP185––a gift from J. Berger) and mu-
tants E66Q or I1121V (HFP271, HFP273) were expressed
as previously described (23). For WT and E1109Q Uls1 ex-
pression (HFP 385, HFP404), plasmids were transformed
into HFY155. 6L of YPLG media was inoculated (1:10 ra-
tio) with a saturated overnight culture (SC-URA) and in-
cubated at 30◦C for 16 h. Protein expression was induced
by the addition of 2% galactose (final) and the culture har-
vested after 6-h cultivation at 30◦C. A cryogenic grinder
was used to disintegrate yeast cells. The powder was diluted
in Lysis buffer (50 mM HEPES; pH 7.4, 500 mM NaCl,
10 mM imidazole, 10% glycerol, 0.5% Triton X-100 and
ethylenediaminetetraacetic acid (EDTA)-free protease in-
hibitors (Roche)) and spun at 35 000 g for 1 h at 4◦C. The
supernatant was incubated for 30 min with TALON resin
(Clontech), washed extensively with TALON wash buffer
(50 mM HEPES; pH 7.4, 500 mM NaCl, 10 mM imida-
zole, 10% glycerol) and eluted with TALON elution buffer
(50 mM HEPES; pH 7.4, 500 mM NaCl, 200 mM imida-
zole, 10% glycerol). The eluted protein was loaded onto a
Strep-Tactin XT column 1 ml (IBA), washed with Strep-
Tactin wash buffer (50mMHEPES; pH 8.0, 200mMNaCl,
10% glycerol) and eluted by Strep-Tactin elution buffer (50
mMHEPES; pH 8.0, 200 mMNaCl, 10% glycerol, 50 mM
Biotin). The eluted protein was concentrated using a 10
kDaMWCOAmicon spin column, frozen in liquid N2 and
stored in small aliquots at −80◦C.
In vitro protein interaction assay
Top2 (prey) was expressed and purified as described above.
To obtain the bait protein, BL21(DE3)RIL Escherichia coli
was transformed with the relevant plasmids (HFP219,
HFP221, HFP222). The cells were grown in TB medium at
37◦C until OD600 = 0.4–0.6. Expression was induced with
0.5 mM Isopropyl -D-1-thiogalactopyranoside (IPTG)
and left for 16–18 h at 16◦C. The pellets were resuspended
in Lysis buffer, sonicated and centrifuged at 4◦C, 20 000 g
for 1 h. The supernatants were added onto TALON resin
(Clontech) and incubated at 4◦C for 40 min. The resins
were washed with TALON wash buffer and eluted with
TALON elution buffer. Approximately 0.1 mg of bait pro-
tein was pre-bound with 80 l of Strep-Tactin superflow
(IBA) beads and washed with Pulldown buffer (25 mM
HEPES; pH 7.5, 150 mM KCl, 3 mMMgCl2, 5% glycerol,
1 mMDTT, 0.1%NP-40). A total of 200 l of the prey pro-
tein (0.1 mg/ml) was added to the beads and incubated to-
gether with the bait or empty beads for 1 h at 4◦C. Then
the beads were washed three times with Pulldown buffer
and 20 l of 5× sodium dodecyl sulphate (SDS)-Sample
buffer was added directly to the beads and boiled together
with input and flowthrough fractions. The bound fraction
is ∼20× more concentrated than input and flow through
fractions.
Topoisomerase activity assays
Decatenation assays were performed using a Topoiso-
merase II Assay kit (TopoGEN, TG1001-1) except with
yeast Top2. The reaction was incubated for 30 min at 30◦C
and terminated by the addition of 5× Stop buffer. Samples
were loaded onto a 1% agarose gel containing 0.5 g/ml
of ethidium bromide and run for 1 h at 4 V/cm. Plasmid
linearization assays were performed as described previously
(24) with minor modifications. The reaction volume was 20
l. A total of 2 l of 1 M Top2 (homodimer) was added
into the tube containing 5 nM pUC19 vector (166.7 ng),
± etoposide or acriflavine in appropriate concentration and
2 l of 10× reaction buffer (500 mMTris·Cl; pH 8, 100 mM
MgCl2, 5mMdithiothreitol, 1.5MNaCl, 300g/ml bovine
serum albumin (BSA)). The mixed reaction was incubated
at 30◦C for 15 min.
The reaction was terminated by adding 2 l of 10% SDS.
Then 1.5 l of 250 mM EDTA and 2 l of 1 mg/ml pro-
teinase K was added, incubating for 2 h at 50◦C. Samples
were loaded on a 1% agarose gel containing 0.5 g/ml EtBr
with electrophoresis carried out for 3 h at 4 V/cm.
ATPase assay
An enzyme-coupled ATPase assay based on hydrolysis of
ATP coupled to oxidation of NADH was used to mea-
sure the protein ATPase activity (25). A total of 15 nM
Uls1 and/or 50 M homodimeric Top2 alone or with
100 M DNA (purified sheared salmon-sperm DNA, In-
vitrogen) were mixed together in a buffer containing 50
mM Tris.HCl; pH 7.9, 100 mM KCl, 8 mM MgCl2,
5 mM beta-mercaptoethanol, 200 g/ml BSA, 2 mM
Phospho(enol)pyruvate, 280 M NADH (Sigma, N7410),
0.5 mM ATP and 1 l of pyruvate kinase/lactate dehydro-
genase mix (Sigma, P0294). The reactions were performed
in 100l reaction volume in a 96-well plate at 30◦C. The ox-
idation of NADH to NAD+ was monitored by measuring
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of the fluorescence (Excitation––340 nm, Emission––440m)
every 30 s for 30 min using a Spectramax Gemini XPS mi-
croplate reader. Titration of increasing concentration on
NADH was used to obtain a standard curve for each mea-
surement. The background signal was subtracted from each
sample before plotting the results into the graph.
Chromatin immunoprecipitation
Cells were grown to OD600 of 0.6, split in two and then in-
cubated with or without ACF for two hours. Yeast in ACF
containing media were spun and re-suspended in an equiv-
alent volume of fresh YPD before crosslinking with 1%
formaldehyde for 10 minutes and quenching with 140 mM
glycine.
Yeast were disrupted using homogenization beads
(0.5 mm diameter, Thistle Scientific 11079105) in 200 l
lysis buffer (50 mM HEPES pH 7.5, 140 mM NaCl, 1 mM
EDTA, 1% Triton X-100, 0.1% sodium deoxycholate,
protease inhibitors). They were bead beaten in a FastPrep
disruptor for 5 × 30 s at power setting 6.5, with cooling on
ice between each cycle. Lysates were diluted in a further 300
l lysis buffer and spun for 15 min at 15 000 rpm at 4◦C.
The pellet was resuspended in 300 l lysis buffer in a 1.5
ml Bioruptor tube (Diagenode, C30010016) and chromatin
sheared using a Bioruptor Pico, 10 cycles of 30 s on/off
(DNA should be sheared to fragments of 250–500 bp).
This was centrifuged at 8000 rpm for 5 min at 4◦C and the
supernatant used for ChIP.
A total of 25 l magnetic Protein A/G beads (Fisher,
11844554) and 1 g antibody (anti-FLAG: Sigma, F3165
or anti-HA: Roche, clone 3F10, ROAHAHA) per test con-
dition are added to 500 l 5 mg/ml PBS–BSA which is ro-
tated for 1 h at 4◦C. This was washed with lysis buffer and
then incubated with ChIP extract for 3 h at 4◦C. Beads are
washed twice with lysis buffer for 5 min and then twice with
wash buffer (100 mM Tris pH 8, 250 mM NaCl, 0.5% NP-
40, 0.5% sodium deoxycholate, 1 mM EDTA, protease in-
hibitors) before elution in 60 l TE, 1% SDS at 65◦C for 15
min.
To prepare protein samples for gel-electrophoresis, sam-
ples are un-crosslinked by boiling at 95◦C for 15 min be-
fore loading onto the gel. To prepare DNA for purification,
1% SDS is added to input, 0.5 l RNase A (10 mg/ml) is
added to both input and IP DNA, and both samples are
un-crosslinked overnight at 65◦C in a polymerase chain re-
action (PCR) machine. A total of 0.5 l Proteinase K (20
mg/ml) is added after uncrosslinking and samples incu-
bated for 1 h at 65◦C. DNA was purified using Qiagen QI-
Aquick PCR purification kit (Qiagen, 28106) as per specifi-
cations, eluting in 50 l H2O.
DNA sequencing and ChIP-seq analysis
Adaptor sequences were ligated onto ChIPed DNA using
T4 DNA ligase and amplified using Phusion DNA poly-
merase. This was run on a 1% agarose gel to remove adap-
tor sequences and the amplified DNA excised and pu-
rified using Qiagen MiniElute columns. Next generation
DNA sequencing was carried out at Tayside Centre for
Genomic Analysis. Sequencing quality was checked using
FASTQC (26) and adapters removed using cutadapt (27).
Reads were mapped to the Saccharomyces cerevisiaeW303
genome using BWA (28). Peak calling was carried out using
MACS2 (29) and differential analysis comparing peak re-
gions between different datasets was performed using BED-
Tools (30). A detailed description of library preparation and
bioinformatics analysis (Supplementary methods) can be
found in supplementary information.
RESULTS
Excess Top2 activity is toxic to uls1Δ cells
Deletion of ULS1 does not result in a dramatic growth de-
fect or in sensitivity to a variety of DNA damaging drugs
(Supplementary Figure S1A). This apparent absence of
phenotype initially hindered our attempts to understand
its function. However, a previous large-scale chemogenetic
screen identified ACF as a drug that specifically kills uls1Δ
yeast (31) and we confirmed the potent toxicity of ACF
(Figure 1A). ACF has been described as having antibacte-
rial (32), antimalarial (33) and anti-cancer properties (34).
This broad range of activity is likely due to the fact that
ACF inhibits type II topoisomerase activity in vitro (33,35).
We show that in budding yeast, ACF acts as a Top2 poi-
son rather than as a Top2 catalytic inhibitor. ACF stabilizes
Top2 cleavage complex formation in vitro and ACF toxicity
is enhanced by Top2 over-expression in vivo (Supplemen-
tary Figure S1B and C)––both hallmarks of Top2 poisons.
Our data are consistent with a previous study showing that
acriflavine stabilizes the formation of type II topoisomerase
cleavage complexes within trypanosome mitochondria in
vivo (36). To explore the pathways targeted byACF in yeast,
we isolated spontaneous ACF suppressor mutants of uls1Δ
strains in a forward genetic screen. Of the eight indepen-
dent suppressor colonies tested, all contained single point
mutations within TOP2, two of which were identified mul-
tiple times (Figure 1B). Furthermore, the ACF-dependent
sensitivity of uls1Δ strains is suppressed by top2-1mutation
at its semi-permissive temperature but not by loss of Top1
(Supplementary Figure S1D). These data show that Top2 is
the most significant factor mediating ACF toxicity in yeast.
To test whether uls1Δ cells are generally sensitive to Top2
poisons, we additionally tested the Top2 poison, ellipticine.
This was done in a sensitizing rad51Δ genetic background
to more accurately detect an effect, as ULS1 has previously
been shown to have genetic interactions with mutants of the
homologous recombination DNA repair pathway (37,38).
We find that ULS1 deletion results in sensitivity to ellip-
ticine only in a sensitizing background (Supplementary Fig-
ure S2A). This may reflect subtle differences in the mode of
drug action (39,40) or uptake. Indeed, Top2 poisons such as
etoposide are poorly taken up by yeasts, meaning that drug
sensitivity in wild-type cells is typically only observed in ge-
netic backgrounds that contain plasma membrane pump
mutations (20,41). In contrast, we find that ACF uptake
from agar plates is very efficient, even in strains without
membrane pump mutations. We have taken advantage of
this to carry out a genome-wide deletion library screen
for ACF sensitivity in an otherwise wild-type yeast back-
ground, which will be published elsewhere. We introduced
the TOP2 alleles identified in our ACF suppressor strains
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Figure 1. ULS1 deletion causes sensitivity to ACF due Top2 activity. (A) The 10-fold serial dilutions of WT (HFY9) or uls1Δ (HFY71) yeast on rich
media (YPD) or drug containing plates (ACF). (B) Identification of isolated suppressor mutants and their location within the structure of the Top2 dimer
(PDB ID: 4GFH). (C) Top2 point mutations were introduced into independent yeast strains to verify they are causing suppression. top2 I1121V (HFY264)
and top2 Y510C (HFY263) alleles fully supress the ACF sensitivity of uls1Δ (HFY71) such that the grow identically to WT (HFY9) on ACF. (D) In vitro
decatenation assay. A total of 200 nM of kinetoplastid DNA was incubated for 30 min at 30◦C with 0, 3, 6, 12, 25, 50 or 100 nM Top2 before being run
out on a 1% agarose gel. Top2 containing the suppressor mutation I1121V (HFP273) is ∼16-fold less active than wild-type Top2 (HFP 185) but still has
significantly more activity than the ATPase dead Top2 E66Q (HFP271). A Coomassie-stained protein gel on the right illustrates the purity of expressed
Top2 constructs.
into independent yeast strains. This confirmed that the sup-
pression phenotype observed was solely due to mutations
in TOP2 and not of any other factor (Figure 1C). The sup-
pression of the initial uls1Δ ACF sensitivity was complete
as uls1Δ top2 I1121V or uls1Δ top2 Y510C double mutant
cells grew indistinguishably fromwildtype (Figure 1C). This
further reinforces the notion that Top2 is the key target of
ACF in vivo. Whilst we cannot exclude that ACF affects
other cellular pathways, if it does, they do not significantly
affect cellular growth or viability.
The ACF suppressor mutations identified did not cluster
within the three-dimensional Top2 protein structure (Figure
1B), making it unlikely that they were affecting a protein–
protein interaction. Instead, we hypothesized that the sup-
pressor mutations were influencing Top2 catalytic activity.
To test this, we purified wild-type and mutant yeast Top2
and carried out in vitro decatenation reactions. As seen in
Figure 1D, Top2 I1121V was able to unlink the interlocked
rings of kinetoplastid DNA, in contrast to the ATPase dead
Top2 E66Q allele. However, Top2 I1121V was∼16-fold less
active than wild-type. These data are consistent with ACF
acting as a Top2 poison as reduced Top2 enzymatic activity
results in lower drug toxicity. Consequently, the most likely
reason that uls1Δ cells are more sensitive to ACF than wild-
type is that they have increased Top2 activity. This antago-
nism between Uls1 and Top2 is not just drug dependent as
overexpression of Top2 is toxic to uls1Δ yeast, even in the
absence of ACF (Supplementary Figure S1B).
Amino acids 350–650 within Uls1 mediate physical interac-
tion with Top2
Having established a genetic interaction between Top2 and
Uls1, we asked the question whether these two proteins in-
teract physically. Using a yeast 2-hybrid (Y2H) assay, we
detected weak but reproducible binding between full-length
Uls1 and full-length Top2 in vivo. Furthermore, we could
narrow down the region of Uls1 required for Top2 inter-
action to fragment 350–655 (Figure 2A). To verify that the
Uls1-Top2 binding interaction observed was direct, we as-
sayed their ability to interact in vitro. Using purified pro-
teins, we confirmed that Uls1 fragment 350–655 binds to
Top2 in vitro (Figure 2B). This region of Uls1 contains sev-
eral putative SUMO-interaction motifs (SIMs) (42) and is
able to bind SUMO by Y2H assay (Supplementary Figure
S3A).Moreover, Top2 can be sumoylated in vivo (43). How-
ever, the purified Top2 used in our in vitro binding assays
had no detectable sumoylation, as determined bymass spec-
trometry (data not shown). Therefore, Uls1 binding to Top2
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Figure 2. Physical interaction of Uls1 and Top2 is important for Uls1 function. (A) Yeast 2-hybrid assay. Yeast containing the indicated combination of
Gal4 activator domain (pOAD) and Gal4 binding domain (pOBD) plasmids were grown on control (-LW) plates and assay (-LWH with 5 mM 3-Amino-
1,2,4-triazole) plates. Full length Uls1 (HFP136) andUls1 350–655 (HFP133) interact with Top2 (HFP 185) but not the empty vector control (HFP122). In
contrast, Uls1 fragments 1–350 (HFP193) and 655–1619 (HFP134) do not bind Top2. (B) in vitro pulldown of full length Top2 with the indicated fragments
of Uls1 bound to agarose beads showing input (I), flow-through (FT) and bound (B) fractions. (C) Diagram of Uls1 domain architecture. Serial dilutions
of the indicated genotypes were assayed for viability on 250 MACF. Mutation of Uls1 ATPase function (uls1 E1109Q-HFY275) or deletion of its Top2
interaction domain (uls1 Δ350-655-HFY225) mimics uls1Δ (HFY71). In contrast, mutation of ULS1′s RING finger (uls1 C1385S-HFY230) has hardly
any effect on ACF sensitivity whereas mutation of its five putative SIMs (HFY261) has a moderate effect on ACF sensitivity. (D) Western blot of the same
constructs used in C, indicating equivalent expression levels. Ponceau-stained membrane is used a loading control.
is unlikely to require Top2 sumoylation, although it might
be enhanced by it.
To assess the functional significance of Uls1–Top2 inter-
action, we introduced a range of mutations into the endoge-
nous ULS1 gene and FLAG-tagged it to monitor its ex-
pression level. Strikingly, deletion of the Top2 interaction
domain, uls1 Δ350-655, mimicked complete loss of ULS1
(Figure 2C). In contrast, mutating all predicted SIMs in
Uls1 resulted in only moderate ACF sensitivity. These data
show that Top2 interaction is essential for Uls1 activity
whereas SUMO-binding merely promotes it. As expected
for a Snf2-family enzyme, mutating the Walker B motif
(E1109Q) within the ATPase domain of Uls1 completely
inactivated its function. However, mutating Uls1′s RING
domain (C1385S) had no significant effect (Figure 2C). It is
important to note that none of the phenotypes observed are
due to altered Uls1 protein levels (Figure 2D). Uls1 has pre-
viously been proposed to act as a SUMO-targeted Ubiqui-
tin Ligase (STUbL), with SUMO-targeting being mediated
via its SIMs and the RING domain acting as an E3 Ubiq-
uitin ligase (42). However, in the context of ACF resistance,
we see that Uls1′s RING domain is dispensable, and that
SIMs play an important but non-essential role. Therefore,
it appears unlikely that Uls1 is acting as a STUbL on Top2
and indeed, Top2 protein levels do not change significantly
in uls1Δ strains compared toWT, neither in the presence or
absence of ACF (Supplementary Figure S3B and C). How-
ever, we cannot exclude the possibility that that the absence
of ULS1 has an indirect effect––perhaps by affecting Slx5/8
StUbL activity.
Uls1 has weak DNA stimulated ATPase activity
ATP-hydrolysis is an essential feature of all Snf2 proteins
(1). To characterize Uls1′s ATPase activity, we attempted to
purify the full-length protein from yeast. However, Uls1 is
a large (184 kDa), low abundance protein and overexpress-
ing it in yeast or Sf9 insect cells gave very poor yields. We
noticed that deleting the first 349 amino acids of Uls1 re-
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Figure 3. Uls1 has DNA-stimulated ATPase activity. (A) Scheme of the coupled ATPase assay used, reactions were carried out at 30◦C and A340 mea-
surements taken every 10 s for 30 min. (B) ATP hydrolysis rates for the indicated proteins. The graph shows the average ± the standard deviation of three
independent experiments. A total of 15 nMUls1 was incubated with or without 100 M salmon sperm DNA. (C) A Coomassie-stained protein gel on the
right illustrates the purity of the purified Uls1 constructs Uls1 1-349 (HFP385) and Uls1 1-349, E1109Q (HFP404).
sulted in a significant increase in yeast expression (data not
shown). Amino acids 327–350 contain a predicted nuclear
localization signal. However, in terms of catalytic function,
the Uls11-349 protein is fully active (Supplementary Fig-
ure S3D) and therefore suitable for biochemical characteri-
zation.
Uls1 ATP hydrolysis was monitored via a coupled en-
zymatic reaction utilizing pyruvate kinase and lactate de-
hydrogenase to oxidize NADH (25) (Figure 3A). We find
that Uls1 displayed weak DNA-stimulated ATPase activity
(Figure 3B). This ATPase activity is due to Uls1 and not
a contaminating protein as it was abolished in an ATPase
mutant (E1109Q) version of Uls1 (Figure 3B and C). We
also tested whether Uls1′s ATPase activity would be acti-
vated by Top2 in vitro. However, we were unable to detect
any measureable Uls1-dependent increase in ATPase activ-
ity in the presence of Top2 (Supplementary Figure S4A and
B). This was also true if we used a version of Top2 with
a 5×SUMO tag on its C-terminus to mimic endogenous
sumoylation (data not shown). These assays were hampered
by the very low amounts of Uls1 that we were able to pu-
rify. It is possible that the concentrations of Uls1 used may
be below its association constant for Top2 or that we have
not used appropriate reaction conditions, making it difficult
to draw strong conclusions from these experiments. How-
ever, importantly, we have been able to show that purified
Uls1 has DNA-stimulated ATPase activity. To the best of
our knowledge, all Snf2-family enzymes tested have shown
DNA-stimulated ATPase activity in vitro as they all act on
DNA-bound substrates in vivo (8,44–46). Therefore, Uls1
behaves functionally as a bone fide Snf2 protein.
Deletion of ULS1 results in a global increase in acriflavine-
stabilized Top2 on DNA
Because of the antagonistic relationship between Uls1 and
Top2 activity (Figure 1B andD), we decided to test whether
Uls1 influenced Top2 localisation in vivo. To this end, we
performed ChIP-seq on strains with an extra HA-tagged
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Figure 4. Uls1 controls Top2 chromatin binding in the presence of ACF. (A) Pairwise comparison of the average ChIP enrichment across all mapped reads
(Genome) and specifically within common regions called as peaks by MACS2 (Peaks) in wild-type cells (HFY250) both in the presence or absence of 250
M ACF. Top2 peaks become significantly more intense when ACF is added, Cohen’s d = 0.49. (B) The same as in A, except in uls1Δ cells (HFY252)
showing that the effect of ACF is exacerbated, Cohen’s d = 1.56. (C) Pairwise comparison of the average ChIP enrichment in the presence of 250 M
ACF. Comparing common ACF-dependent peaks between wildtype (HFY250) and uls1Δ (HFY252) cells indicates that there is significantly more Top2
bound in uls1Δ, Cohen’s d = 0.62. (D) Association of Top2 peaks within genes and the expression level of those genes in asynchronous culture under
exponential growth. Expression data were taken from (45) and the number of peaks within each group is displayed next to the graph. (E) Normalized Top2
peak probability relative to the TSS of RNAP II transcripts in wild-type (HFY250) or uls1Δ (HFY252) cells in the presence or absence of ACF. The solid
line displays the average with 95% confidence intervals indicated by the shaded area.
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Figure 5. Uls1 binding sites do not accumulate Top2 in the presence of ACF. (A) Pairwise comparison of the average Uls1 ChIP enrichment (HFY176)
across all mapped reads (Genome) and specifically within peak regions ± 100 MACF. The level of Uls1 chromatin binding is independent of ACF. (B)
NormalizedUls1 peak probability relative to the TSS of RNAPol II transcribed genes in the presence or absence of ACF. The solid line displays the average
with 95% confidence intervals indicated by the shaded area. (C) Comparison of the average Top2 ChIP enrichment (using filtered reads) between regions
that are either bound or unbound by Uls1± 250 MACF. In contrast to unbound sites, Uls1 binding sites do not accumulate Top2 in the presence of ACF.
This effect is ULS1 dependent. (D) Pairwise comparison of the average Uls1 ChIP enrichment using unfiltered reads across the genome and specifically
within tRNA genes ± 100 MACF. Uls1 becomes enriched at tRNA genes in the presence of ACF, Cohen’s d = 1.16. (E) Same as (D) except looking at
Top2 ChIP. ACF causes loss of Top2 from tRNA genes, which is ULS1 dependent.
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B
Figure 6. Model of how Uls1 and acriflavine influence Top2 DNA binding. (A) Summary of ChIP data describing how Uls1 antagonizes the ACF-
dependent increase in Top2 binding throughout the genome. (B)Model of howUls1might remodel a Top2 cleavage complex by promotingDNA-stimulated
Top2 ATPase activity leading to movement of the transfer DNA (grey) and resolution of the Top2-DNA bonds within the guide DNA (black). Given that
uls1Δ cells appear to have fewer Top2 peaks in the absence of ACF, it is possible that Uls1 may have an indirect role in promoting initial Top2 binding to
DNA.
copy of TOP2 under the control of its endogenous pro-
moter in wild-type (HFY250) and uls1Δ (HFY252) cells
both in the presence and absence of 250 M ACF. These
strains were used as they show the expected ACF sensi-
tivity in a uls1Δ background. In contrast, a uls1Δ strain
where only the endogenous copy of TOP2 is HA-tagged has
suppressed ACF sensitivity (Supplementary Figure S3B).
Four independent ChIP replicates of each condition were
pooled to form two DNA sequencing replicates which were
aligned to the W303 genome reference (47) using BWA (28)
and subjected to automated peak calling by MACS2 soft-
ware (29). As expected of a Top2 poison, we saw that ACF
caused an increase in the number of Top2 peaks called (Sup-
plementary Figure S5A). Importantly, ACF also caused a
significant increase in the intensity of Top2 peaks. Due to
the large number of data points involved, statistical signifi-
cance was assessed using Cohen’s d (d), which measures ef-
fect sizes based on the difference between two means. Co-
hen’s d-values of 0.2, 0.5 or 0.8 typically denote a small,
medium or large effect, respectively (48). By performing a
pairwise comparison of common peaks, we saw that the
addition of ACF resulted in a modest increase (d = 0.49)
in the average Top2 peak intensity in wildtype cells (Fig-
ure 4A). Strikingly, the increase in Top2 peak intensity af-
ter ACF treatment in a uls1Δ strain (Figure 4B) was much
more pronounced (d = 1.56). By directly comparing com-
mon Top2 peaks between wild-type and uls1Δ cells exposed
to ACF, we could confirm that significantly more Top2 (d
= 0.62) becomes DNA-bound in uls1Δ cells compared to
wild-type (Figure 4C). These data explain the genetic inter-
actions we had seen and suggest that uls1Δ cells exposed
to ACF die because an excessive amount of Top2 becomes
bound to chromatin. The changes in Top2 binding are un-
likely to be due to altered cell cycle profiles as, over the
time course of our experiments, we only observemildG2/M
arrest in ACF treated uls1Δ cells (Supplementary Figure
S5B). Top2 ChIP qPCR in strains where only the endoge-
nous TOP2 gene isHA-tagged confirmed the trendswewere
seeing via ChIP-seq (Supplementary Figure S5C). These
data also suggest that TOP2 copy number does not bias
ACF-dependent changes in Top2 chromatin association.
Top2 is known to be associated with ongoing transcrip-
tion (49). Consistentwith this, we find thatwhenTop2 peaks
are near genes, these are highly expressed under conditions
of exponential growth (50) (Figure 4D). The addition of
ACF results in an overall increase in Top2 peak number
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as well as the distribution of peaks becoming much less bi-
ased toward highly expressed genes. This shows that ACF-
dependent Top2 peaks are associated with genes but are
largely uncoupled from their initial transcription level in un-
perturbed cells. Interestingly, a similar trend in seenwith hu-
man cells, where TOP2A-dependent cleavage complex for-
mation within protein coding genes is independent of tran-
scription level (51). By plotting Top2 peak probability rel-
ative to the transcription start site (TSS) of the ‘average’
RNA Pol II transcribed gene, we find that Top2 is more
likely bound within gene bodies both inWT and uls1Δ cells
(Figure 4E). Interestingly, this pattern is largely unchanged
when WT cells are exposed to ACF. In contrast, uls1Δ cells
exposed to ACF display a dramatic change such that Top2
peaks are now more likely to be found upstream of the
TSS within intergenic regions rather than within coding se-
quences (Figure 4E). Therefore, uls1Δ cells exposed to ACF
not only have increased levels of Top2 bound to DNA but
its distribution across genes becomes markedly disrupted.
Uls1-bound regions do not accumulate Top2 after exposure
to ACF
We decided to map Uls1 binding sites by performing ChIP-
seq on a FLAG-tagged Uls1 strain in the presence and ab-
sence of ACF. We used 100M ACF as Uls1 activity is
essential at this concentration (Supplementary Figure S2B
and C) and higher drug concentrations disrupted Uls1 pull-
down (data not shown). Overall, there was a slight decrease
in the number of unique Uls1 peaks in the presence of ACF
and no significant change (d = 0.05) in the average Uls1
peak intensity (Figure 5A). This indicates that the absolute
level of chromatin-bound Uls1 remains largely unchanged
by ACF. However, ACF does re-distribute Uls1 to regions
upstream of RNA Pol II genes (Figure 5B).
To test our hypothesis that Uls1 was directly influencing
Top2 in vivo, we compared the behaviour of Top2 peaks that
either did or did not overlapwithUls1 peaks. At Top2 peaks
that do not overlap with Uls1, ACF caused an increase in
the amount of Top2 bound to DNA and this effect was ex-
acerbated in uls1Δ cells (Figure 5C). This was similar to the
trends we had observed previously (Figure 4A andB).How-
ever, strikingly, at Top2 peaks that overlap with Uls1, ACF
did not cause any significant increase (d = 0.08) in Top2
levels. Importantly, in uls1Δ cells, the addition of ACF re-
sulted in an increase (d= 1.03) in Top2 binding at these sites
(Figure 5C). These data support the model that Uls1 acts to
remove Top2 trapped on chromatin by ACF.
When we looked specifically for ACF-dependent Uls1
binding sites, tRNA genes stood out. These accounted for
21% of all Uls1 peaks in the presence of ACF, but only
4% in untreated cells (Supplementary Figure S6A). Most
tRNA genes are duplicated in the yeast genome, with some
present in as many as 16 copies per cell (52). Our standard
bioinformatic analysis filters out sequence reads that map
to multiple genomic locations. Therefore, due to their repet-
itive nature, we might be missing relevant information. By
analysing unfiltered sequence reads, we see that Uls1 sig-
nal at tRNAs increases significantly (d = 1.16) after the ad-
dition of ACF (Figure 5D). Indeed, after looking at other
repetitive loci (telomeres, rDNA and Ty retrotransposons),
tRNAgenes are the only regionswhereUls1 signal increases
significantly after ACF treatment (Supplementary Figure
S6B). Importantly, we also observe an antagonistic relation-
ship between Uls1 and Top2 at tRNA genes. ACF caused
a significant decrease (d = 1.02) in Top2 signal at tRNA
genes which was ULS1-dependent (Figure 5E). Thus, the
presence of Uls1 prevents ACF-dependent Top2 accumula-
tion at tRNA genes as it does at other genomic loci.
DISCUSSION
We show here that Uls1 can suppress Top2 activity by re-
moving Top2 that becomes chromatin-bound when cells
are exposed to the Top2 poison ACF. Our ChIP procedure
cannot differentiate between a true Top2 cleavage complex
and Top2 that is non-covalently bound to DNA. However,
the distribution of ACF-dependent Top2 peaks in yeast are
consistent with the behaviour of bona fide TOP2A cleav-
age complexes in human cells (51) as both are independent
of transcription level. This suggests that Top2 poisons are
opportunistic in their mode of action and will trap Top2
molecules wherever they are found.
Although ACF leads to a general increase in Top2 bind-
ing to chromatin, there are a few regions including ribo-
somal protein genes (Supplementary Figure S5D), tRNA
genes and the rDNA locus (Supplementary Figure S6C)
where ACF resulted in a decrease in the amount of Top2
bound. It is not immediately clear why ACF should cause
less Top2 to be DNA-bound at these sites. However, it is
possible that stalled Top2 at these highly transcribed genes
is more easily detected and targeted for degradation. In-
deed, one of the main mechanisms of recognizing Top2
adducts is via collision with the transcription machinery
(53). Overall, the effects of ACF become exacerbated when
ULS1 is deleted: more Top2 peaks are found and their sig-
nal intensity is higher, consistent with more Top2 becom-
ing chromatin-bound. We see that Uls1 tends to bind close
the to 5′ end of RNA Pol II gene coding regions, in agree-
ment with what has been observed for several other Snf2
proteins (54,55). In the presence of ACF, a significant frac-
tion ofUls1 relocalizes to tRNAgenes. Importantly, at Uls1
peaks, there is no ACF-dependent increase in chromatin-
boundTop2, suggesting thatUls1 removes Top2 fromDNA
(Figure 6A and B).
We do not always see a direct anti-correlation between
DNA-bound Top2 and Uls1. This may, in part, be because
there is almost 30 times more Top2 than Uls1 in a yeast
cell (56). Consequently, deletion of ULS1 results in ACF-
dependent changes in Top2 binding at far more sites than
we see Uls1 binding to. We cannot exclude that some of
these effects are indirect. Moreover, Uls1-Top2 interaction
may be dynamic and so Uls1 may only interact transiently
at any given site before dissociating away to bind another
region. This is not atypical for Snf2 proteins whose ATPase
activity can influence substrate binding (57,58).
The precise mechanism by which Uls1 remodels Top2 to
release it from the cleavage complex is uncertain. We see
that Uls1 function is completely dependent on its ATPase
activity, partially dependent on SUMO interaction and in-
dependent of its RING domain. This suggests that, at least
within this context, Uls1 is not acting as a STUbL to de-
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grade proteins (42). Snf2 proteins are known to translocate
along DNA in an ATP-dependent manner (59). We there-
fore speculate that Uls1 may use its DNA translocase ac-
tivity to alter Top2–DNA interactions. This may displace
Top2 from DNA or potentially alter the precise orientation
of DNA within a Top2 cleavage complex and so stimulate
Top2′s intrinsic ATPase activity to release itself from DNA
(23). It is not clear at this stage why Uls1 is recruited to
tRNA genes to remodel Top2. There is very little published
literature linking tRNAgeneswithTop2.However, topoiso-
merase activity appears to be largely dispensable for tRNA
transcription in yeast (60). Therefore, it is possible that Uls1
is being recruited to tRNA genes to deal with stalled Top2
not because of an effect on tRNA expression but because
of replication fork arrest, which occurs primarily at tRNA
genes in yeast (61). Indeed, we do not observe dramatic
changes in tRNA levels in either WT or uls1Δ cells exposed
to ACF compared to YPD (Supplementary Figure S6D).
However, given the long half-lives of tRNAs and the fact
that we are looking at rather short exposure times to ACF,
it is difficult to exclude transcriptional effects altogether.
Utilizing Uls1 to remodel trapped Top2 may be partic-
ularly important in lower eukaryotes. Although Tdp1 is
able to process both Top1 and Top2 complexes (62), yeasts
lack Tdp2 which specifically cleaves the 5′-phosphotyrosyl
bond within covalent Top2–DNA complexes in mammals
(63,64). It remains to be seen whether mammalian ho-
mologs of Uls1 can carry out analogous Top2 remodelling
reactions. If so, it opens up the possibility of targeting these
Snf2 proteins in combination with Top2 poison treatment
to potentiate anticancer therapies.
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